Table 2.
The association of PSCA and Oct-4 expression with the clinicopathological characteristics of gallbladder adenocarcinoma.
| Clinicopathological characteristics | Total no. | PSCA | Oct-4 | ||||
|---|---|---|---|---|---|---|---|
| Pos. nos. (%) | χ2 | P | Pos. nos. (%) | χ 2 | P | ||
| Sex | |||||||
| Male | 31 | 16 (51.6) | 0.16 | >0.05 | 17 (54.8) | 0.01 | >0.05 |
| Female | 77 | 43 (55.8) | 43 (55.8) | ||||
| Age (years) | |||||||
| ≤45 | 24 | 14 (58.3) | 0.17 | >0.05 | 16 (66.7) | 1.54 | >0.05 |
| >45 | 84 | 45 (53.6) | 44 (52.4) | ||||
| Differentiation* | |||||||
| Well | 36 | 14 (38.8) | 15.12 | <0.01 | 13 (36.1) | 13.31 | <0.05 |
| Moderately | 31 | 16 (51.6) | 18 (58.1) | ||||
| Poorly | 30 | 25 (83.3) | 24 (80.0) | ||||
| Mucinous A. | 11 | 4 (36.4) | 5 (45.5) | ||||
| Tumor size (cm) | |||||||
| <2 cm | 31 | 12 (38.7) | 4.47 | <0.05 | 10 (32.3) | 9.56 | <0.01 |
| ≥2 cm | 77 | 47 (61.0) | 50 (64.9) | ||||
| Lymph node metastasis | |||||||
| No | 49 | 19 (38.8) | 8.04 | <0.01 | 19 (38.8) | 10.23 | <0.01 |
| Yes | 59 | 40 (67.8) | 41 (69.5) | ||||
| T stages | |||||||
| T1 | 14 | 5 (35.7) | 7.73 | <0.05 | 4 (28.6) | 17.24 | <0.01 |
| T2 | 35 | 15 (42.9) | 13 (37.1) | ||||
| T3 | 37 | 23 (62.2) | 25 (67.6) | ||||
| T4 | 22 | 16 (72.7) | 18 (81.8) | ||||
| Gallstones | |||||||
| No | 50 | 27 (54.0) | 0.01 | >0.05 | 28 (56.0) | 0.01 | >0.05 |
| Yes | 58 | 32 (55.2) | 32 (55.2) | ||||
*Comparison between well-differentiated and moderately differentiated adenocarcinomas: χ PSCA 2 = 1.09, P > 0.05; χ Oct-4 2 = 3.23, P > 0.05.
*Comparison between wel-differentiated and poorly differentiated adenocarcinomas: χ PSCA 2 = 7.29, P < 0.01; χ Oct-4 2 = 6.98, P < 0.01.
*Comparison between moderately differentiated and poorly differentiated adenocarcinoma: χ PSCA 2 = 6.96, P < 0.01; χ Oct-4 2 = 3.42, P < 0.05.
Mucinous A.: mucinous adenocarcinoma.